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Abstract
Background: Increasing affordability of artemisinin combination therapy (ACT) in the African retail sector could be
critical to expanding access to effective malaria treatment, but must be balanced by efforts to protect the efficacy
of these drugs. Previous research estimates ACT adherence rates among public sector patients, but adherence
among retail sector purchasers could differ substantially. This study aimed to estimate adherence rates to
subsidized, over-the-counter ACT in rural Uganda.
Methods: An intervention study was conducted with four licensed drug shops in Eastern Uganda in December
2009. Artemether-lumefantrine (AL) was made available for sale at a 95% subsidy over-the counter. Customers
completed a brief survey at the time of purchase and then were randomly assigned to one of three study arms:
no follow-up, follow-up after two days or follow-up after three days. Surveyors recorded the number of pills
remaining through blister pack observation or through self-report if the pack was unavailable. The purpose of the
three-day follow-up arm was to capture non-adherence in the sense of an incomplete treatment course ("under-
dosing”). The purpose of the two-day follow-up arm was to capture whether participants completed the full course
too soon ("over-dosing”).
Results: Of the 106 patients in the two-day follow-up sample, 14 (13.2%) had finished the entire treatment course
by the second day. Of the 152 patients in the three-day follow-up sample, 49 (32.2%) were definitely non-adherent,
three (2%) were probably non-adherent and 100 (65.8%) were probably adherent. Among the 52 who were non-
adherent, 31 (59.6%) had more than a full day of treatment remaining.
Conclusions: Overall, adherence to subsidized ACT purchased over-the-counter was found to be moderate.
Further, a non-trivial fraction of those who complete treatment are taking the full course too quickly. Strategies to
increase adherence in the retail sector are needed in the context of increasing availability and affordability of ACT
in this sector.
Background
Artemisinin Combination Therapy (ACT) is the WHO
recommended first-line therapy for Plasmodium falci-
parum malaria in nearly all malaria endemic countries and
is the most effective treatment for the disease [1]. Several
recent papers have stressed the urgency of developing stra-
tegies to stem parasite resistance to artemisinin, as resistant
strains have already been detected [2-4]. The development
of widespread resistance to previous generations of
inexpensive, commonly purchased anti-malarials contribu-
ted to increases in malaria mortality among African
children against a backdrop of overall declines in child
mortality in this region [5,6].
Volumes of ACT purchased and distributed through
private and retail sector channels are increasing substan-
tially [7,8], though availability in retail outlets is still far
from universal [9,10]. Since the majority of malaria
treatment-seeking occurs in these sectors [11], and ACT
is 5 to 24 times more expensive than alternative anti-
malarials [9], price has been a major barrier to transi-
tioning anti-malarial purchases from older, less effective
medicines to ACT [12-15]. The Affordable Medicines
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any medium, provided the original work is properly cited.Facility - malaria (AMFm) is a pilot initiative in seven
African countries that aims to substantially reduce the
price of ACT through subsidies [16]. Through this ACT
price reduction, the AMFm also aims to encourage the
purchase of ACT over artemisinin monotherapies
(AMT), as AMT use can be a serious risk for parasite
resistance to artemisinin-based drugs [17,18]. However,
the AMFm’s ultimate impact in protecting artemisinin
will be inhibited if ACT is being used inappropriately
[19].
Non-adherence to recommended treatment regimens,
resulting in sub-therapeutic drug concentrations is a key
driver of parasite resistance [17,20-22]. Non-completion of
a full standard regimen also exposes patients to recurrent
malaria infections and can increase related morbidity and
mortality [23,24]. Previous studies have estimated a range
of adherence rates to ACT obtained in the public sector,
some finding nearly perfect adherence and others finding
adherence rates as low as 39%, but with estimates varying
importantly with the strictness of the definition, research
methods and context [25-37]. It is questionable to what
extent results from these studies can be generalized
to patients purchasing ACT from private sector outlets
such as licensed pharmacies, licensed and unlicensed drug
shops, and other informal outlets like general stores and
market stands. In most public sector studies, adherence is
measured with home visits to patients who received ACT
free-of-charge after a confirmed malaria diagnosis and
often after receiving counseling, dosing instructions and
side effects warnings from a trained provider who often
supervised the first dose [25,28,29,32-34,37,38]. To the
extent that diagnosis, instructions and supervision can
improve adherence, retail sector adherence rates are likely
to be lower [36]. Patient characteristics could differ impor-
tantly as well, e.g. if people are more likely to visit the pub-
lic sector when the patient is young and the illness is
severe [39,40]. Finally, retail sector customers may only be
able to afford a sub-therapeutic dose of ACT and may
choose to keep pills for the next time a household member
is ill to defray future expense [41]. For all of these reasons,
it may be inappropriate to forecast adherence rates to
ACT provided through the retail sector based on existing
public sector estimates.
As financing and other initiatives aiming to increase
access to ACT reach the substantial share of malaria
patients who seek treatment in the retail sector, it is
increasingly crucial to have estimates of adherence rates
among this population. Understanding ACT adherence
in the retail sector is necessary for developing appropriate
strategies to prevent the emergence of artemisinin resis-
tance. This study estimates adherence rates and explores
associated characteristics among patients purchasing
over-the-counter ACT in Uganda. It is the first study to
use follow-up methods to estimate adherence rates to
subsidized, over-the-counter ACT.
Methods
Study area and context
The study was conducted in Soroti District, a rural area in
Northeast Uganda, over three weeks between November
and December of 2009. Soroti has a very high rate of
malaria transmission, with more than 100 infective bites
per person per year [42]. As common in the rest of
Uganda [42,43], Soroti is a district in which patients fre-
quently access medicines through the private sector, at
formal or informal shops and pharmacies. Artemether-
lumefantrine (AL) is the first-line anti-malarial for uncom-
plicated malaria in Uganda. At the time of the study, AL
was approved for over-the-counter use, but less than 5%
of drug stores carried ACT and the median retail price of
ACT in drug stores was $8.76 [43]. The study took place
roughly a year and a half before the introduction of the
AMFm in Uganda. An ACT subsidy pilot program called
the Consortium for ACT in the Private Sector Subsidy
(CAPSS), run by Medicines for Malaria Venture (MMV)
and the Ugandan Ministry of Health, took place in Uganda
in 2008. Soroti was used as a control district for the eva-
luation of this pilot, but no interventions were conducted
there.
Study population
Brief surveys were conducted at 23 retail outlets (“drug
shops”) in Soroti, with information recorded on location,
shop owner and attendant qualifications and years in busi-
ness, customer traffic, days/hours open and most common
anti-malarials sold. Four shops, all licensed and registered
with Uganda’s National Drug Authority, were selected
from this sample to participate in the study. These shops
were licensed “Class C” outlets, meaning that they can
solely dispense over-the-counter medicines. Drug shops in
Uganda are distinct from pharmacies, which can sell pre-
scription medicines as well, but are typically located in
urban areas. At the time of this study, ACT was in the
process of being approved for over-the-counter dispensing
in Uganda and we received special permission from the
Ugandan Ministry of Health to allow our participating
shops to dispense ACT. The shops that were included in
the study were chosen because they were far apart from
one another, staffed by well-qualified attendants, and were
open a sufficient amount of time with enough customer
traffic for us to obtain our patient sample in a three week
time-frame. All four shops were managed by nursing assis-
tants, were open all seven days a week (except one shop
which was closed on Sunday) and were open from the
early morning until mid-evening. The number of malaria
patients visiting the shop per day ranged from 5 in one
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shops cited Quinine as their most commonly sold anti-
malarial. All four shops were located in the area of their
village known as the trading center, which generally con-
stitutes a grouping of a small number of retail outlets
often including at least one drug shop. None of the shops
were in a very remote location or in a busy town center.
Patients or their caregivers who purchased subsidized
AL from the participating shops–either because they
requested it or because the shop attendant recommended
it–were recruited to enroll in the study immediately fol-
lowing purchase. Pregnant women and infants under four
months of age were excluded from the study since AL is
not approved for this patient population. Patients were
recruited until enrollment reached 395, a sample size
allowing us to detect a projected adherence rate in the
three-day follow-up group of 70% with a 10% margin of
error, a design effect of 2 and 20% loss to follow up.
Intervention design and procedures
Enrollment
Shop attendants participated in a one-day training session
led by a Uganda Ministry of Health-trained professional
on storage, administration, and appropriate use of AL.
With the information and materials obtained during the
training, attendants were instructed to follow their normal
dispensing practices. Shop attendants were trained to refer
any patients who either did not recover after completion
of anti-malarial treatment or who were exhibiting signs of
severe malaria to the nearest public health facility.
Following the training, the study team provided the
selected drug shops with a controlled supply of AL, brand
name Coartem
® manufactured by Novartis, for sale in the
shops. The Coartem treatment package was the standard
packaging commonly available in the private sector, which
is a simple orange and white box with black and red text
on it. Unlike some packaging provided in the public sector,
this packaging included no drawings or visual cues on
appropriate dosing other than a paper insert with written
English instructions printed in black and white. The price
of Coartem to consumers was fixed at 200, 400, 600 or
800 Ugandan Shillings ($0.10 - $0.40 at 2009 exchange
rates) depending on the age/weight band. Shops were per-
mitted to keep 50 Ugandan Shillings on every sale. Prices
were equivalent to those in the CAPSS ACT subsidy pilot
programme [44] and roughly equal to the final retail prices
targeted under the AMFm [45]. A full course of AL con-
sists of six doses, with 1-4 tablets per dose, depending on
bodyweight/age, administered over the course of three
days [46].
All eligible customers who purchased AL and gave con-
sent to be surveyed at the shop were enrolled. The study
team conducted a brief survey at the shop to collect symp-
tom and background information (including the village
and location of the household) and to record observations
regarding the interaction between the shop attendant and
the customer. If the customer was purchasing AL for
another family member or neighbour, the household infor-
mation for both the customer and the patient was
obtained. Neither customers nor patients were informed
of the intent to follow-up or were asked to retain their
blister pack. All questionnaires and informed consent
documents were translated into Ateso, the predominant
language in Soroti. Interviews and informed consent pro-
cesses were conducted in either English or Ateso, accord-
ing to the language preferences of the participant.
Randomization assignment
A pseudo-random number generator in STATA Version
11 (STATA Corporation, College Station, Texas) was used
to create a list that assigned a follow-up assignment to
each patient, based on the order in which they were
enrolled. The project manager had one list numbered 1 to
100 for each shop, with a pre-filled follow-up assignment
for each number. Surveyors enrolling patients at the shop
(and the patients themselves) were blinded to the eventual
follow-up assignment. Participants were randomly
assigned to either no follow-up, follow-up at day two or
follow-up at day three. The aim of the three-day follow-up
was to assess whether patients delayed or discontinued
treatment. The aim of the two-day follow-up was to assess
whether patients finished their entire treatment course too
early. The aim of the no follow-up arm was to introduce
additional uncertainty about the intent to follow up. The
window of time following enrollment for the two-day fol-
low-up arm was between 41 and 55 hours, while for the
three-day follow-up arm it was between 72 and 96 hours.
Follow-up visits
At the household follow-up visit, patients or their care-
givers were again asked for consent to be surveyed. Fol-
low-up questionnaires included sections on demographic
and health background information and household assets
in order to characterize socioeconomic status. Additional
sections focused on the patient’s medicine-taking experi-
ence and behaviour, during which time the surveyor asked
to see the blister pack and recorded the number of tablets
remaining in the pack. If the pack was unavailable or the
participant declined to show the pack, the surveyor asked
the participant how many pills were remaining. Finally,
surveyors reviewed appropriate adherence practices with
the participant. If participants were still feeling ill at the
time of the household visit, enumerators were instructed
to recommend to patients that they visit the nearest public
health facility as soon as possible.
Definition of adherence
Adherence is defined with regard to completion of the
entire age-appropriate treatment course at the three-day
follow-up visit, based on blister pack observation or, in its
absence, self-report. A patient was considered “probably
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and there were no pills left or if no blister pack was avail-
able but the patient reported that all the pills were taken.
A patient was considered “definitely non-adherent” if the
blister pack was available for inspection with pills remain-
ing in the pack and “probably non-adherent” if no blister
pack was available for inspection but the patient reported
that the treatment course was not completed.
Ethical considerations
The study gained approval f r o mt h eU g a n d aN a t i o n a l
Council for Science and Technology (UNCST), Uganda’s
Office of the President, and the Harvard School of Pub-
lic Health Institutional Review Board.
Analysis
Survey data were double entered in CSPro Version 3.1
(U.S. Census Bureau. Washington D.C., USA) and cross-
checked for discrepancies until the error rate calculated
for all sections was below 0.5%. The investigators cleaned
and analysed data using STATA Version 11 software
(STATA Corp., College Station, Texas). Analysis of vari-
ables associated with adherence is conducted in two
ways. First, running probit regressions of the dichoto-
mous variable “probably adherent” (as defined above) on
each of the variables listed in Tables 1 and 2. For this
analysis, coefficient estimates are reported as marginal
effects of the independent variables on the probability of
adherence. The second type of analysis is a series of
ordinary least squares regressions with a variable measur-
ing the number of doses remaining at follow-up (includ-
ing zero if the patient adhered) as the dependent variable
and again with each of the variables listed in Tables 1
and 2 as independent variables. All regressions control
for the shop at which the transaction took place, since
the randomization was stratified by shop [47].
Variables potentially associated with adherence are pre-
sented in Tables 1 and 2. These include (Table 1) socio-
economic status measures (age, gender, marital status,
occupation and assets), education measures (years of edu-
cation, level of education and literacy), health behaviour
measures (bed net usage, water purification and health
system usage), treatment-seeking for this illness episode
(how long the patient waited before seeking any care and
whether or not a health facility was visited or medicines
were taken prior to visiting the drug shop), illness resolu-
tion measures (whether the condition has improved and
the patient can work or play at follow-up and whether the
patient is still experiencing fever), and perceptions of
malaria incidence. Perceptions of malaria incidence were
elicited since this could influence the incentive to save
pills for future malaria episodes. Respondents were asked,
for different age groups, how many babies/children/adults
out of 10 they would expect to get malaria in the next
month. Characteristics of the drug shop transaction (such
as what instructions were given and whether they were
clear) were also recorded based on both direct observation
at the drug shop and self-report by the patient at the fol-
low-up visit.
Results
Description of population and drug shop transaction
Of the 395 enrolled customers, 39 (9.9%) were assigned to
no follow-up, 159 (40.3%) were assigned to two-day
follow-up and 197 (49.9%) were assigned to three-day
follow-up. Loss to follow-up was balanced across groups
at 27 (17%) and 32 (16.2%) in the two and three-day
follow-up groups, respectively. Since the timing of the sur-
vey and blister pack observation is critical for accurate
adherence data, those found beyond the appropriate time
were excluded from the analysis. This includes 26 (16.4%)
patients in the two-day follow-up group and 13 (6.6%) in
the three-day follow-up group, leaving a sample of 106
patients in the two-day group and 152 in the three-day
group. Among those found on time 91.5% (n = 97) and
73.7% (n = 112) showed their blister pack for inspection in
the two-day and three-day groups, respectively. The most
common reasons for not showing the blister pack in the
three-day group were that it was thrown away (58.7%) or
lost (30.4%).
The randomization successfully achieved balance across
observable characteristics (Table 1)–the two follow-up
groups only differed significantly (p = .025) in the share of
patients ages four to seven years. The majority of patients
in the sample were from age groups prescribed the highest
(age 13 and over; ~36%) and lowest (three months
through three years; ~32-40%) doses of AL. The patient
and customer were different in over 70% of cases, but the
great majority of these cases were adult customers buying
medication for a child who was the patient. When the
patient and customer were not the same, the average age
of the patient was 8 and 84% of the patients were 10 or
younger. Since the AL packaging was written in English, it
is important to note that only roughly 40% of patients or
their caregivers could read English. Patients lived on aver-
age just over 2 kilometers from the drug shop and were
for the most part subsistence farmers with low levels of
education. Only about one-quarter of patients visited a
health facility prior to arriving at the shop but more than
half had taken some other medicines before this shop visit.
Although this study was conducted prior to the
AMFm, familiarity with Coartem was high in this popu-
lation, possibly because of experience with the drug
through the public sector. When asked at the follow-up
visit why the patient or caregiver purchased Coartem
half of respondents answered that they believed it was
the most effective anti-malarial and a quarter responded
that they had taken it before and liked it. The majority
of patients/caregivers, when asked which anti-malarial
they prefer if money were no concern stated Coartem
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Two-Day Follow-Up, Mean
(SD)
Three-Day Follow-Up, Mean
(SD)
Observations 106 152
Customer Age (years) 33.4 (11) 33.6 (13)
Customer Sex (Female) 59.4% (49) 57.6%(50)
Customer and Patient Are Same 28.3% (45) 26.7% (44)
Characteristics of Patient/Caregiver
Patient Age (years) 16.4 (19) 17.3 (22)
Patient is 3 years or Below 32.1% (47) 40.8%(49)
Patient is 4-7 Years 26.4%(44) 15.1% (36)
Patient is 8-12 Years 4.7% (21) 7.2%(26)
Patient is 13 Years or Older 36.8% (48) 36.8%(48)
Patient Sex (Female) 59.4% (49) 53.3% (50)
Number of Dependents 5 (3) 5 (3)
Married 84.9% (36) 84.2% (37)
Reads English 39.6% (49) 41.7% (49)
Years of Education 5.5 (4) 5.4 (4)
Some Secondary Education or Beyond 16% (37) 18.4% (39)
Subsistence Farmer 70.8% (46) 77% (42)
Characteristics of Patient/Caregiver’s House and Assets
Distance from Drug Shop (Km; assessed by respondent) 2.1 (2) 2.6 (8)
Land (Acres) 3.6 (3) 3.7 (3)
No Toilet 34.9% (48) 33.6% (47)
Iron Roof 17% (38) 22.4% (42)
Number of Cattle Owned 2.6 (4) 2.9 (6)
Number of Chickens Owned 7.3 (9) 7.1 (9)
Health Behavior
Number of Mosquito Nets Hanging 2.5 (1) 2.4 (1)
First Child Born in Facility (among those with children) 40.4% (49) 36.7% (48)
Treat/Purify Water 9.4% (29) 13.3% (34)
Characteristics of This Illness Episode
Visited a Health Facility Before Shop 23.6% (43) 24% (43)
Days Waited Before Seeking Any Treatment 2.8 (4) 2.9 (4)
Medicines Taken Before Visiting Shop 50.9% (50) 52.3% (50)
Patient Reports Having Fever 58.5% (50) 55.0 (50)
Familiarity with and Perceptions of Coartem
Stated Reason for Purchasing Coartem at Shop: “Believe it is Most Effective” 51.9% (50) 51.3% (50)
Stated Reason for Purchasing Coartem at Shop: “Taken it Before and Liked It” 25.5% (44) 27.0% (45)
Stated Reason for Purchasing Coartem at Shop: “Shop Attendant Recommended” 22.6% (42) 29.6% (46)
If Money Were No Concern, Patient would Choose Coartem 90.2% (30) 82.8% (38)
If Would Choose Coartem, Why: “Believe it is Most Effective” 75.0% (44) 80.8% (40)
If Would Choose Coartem, Why: “Taken it Before and Liked It” 30.4% (46) 30.0% (46)
If Would Choose Coartem, Why: “Shop Attendant Recommended” 10.9% (31) 8.3% (28)
Illness Resolution
Still Experiencing Fever 21.7% (41) 21.5% (41)
Condition Has Improved 93.9% (24) 90.5% (29)
Patient is Able to Work/Play 93.3% (25) 91.8% (27)
Perceptions of Malaria Incidence: “Chances of Getting Malaria in the Next Month
(Out of 10)”
Adults 5.1 (3) 4.8 (3)
Child Age 6-15 6.5 (3) 6.6 (3)
Child Under 2 Years 7.3 (3) 7.4 (3)
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groups, respectively) and again the most commonly sta-
ted reasons for this preference were because it was
believed to be most effective or because they had taken it
before and liked it. Nearly all patients said their condition
had improved and they could work or play at follow-up,
but just over 20% said they were still experiencing some
fever. Respondents’ expectations of the likelihood of
m a l a r i ai nt h en e x tm o n t hw e r ev e r yh i g h –roughly 50%
chance of infection in the next month for adults and
nearly 75% chance for babies.
Nearly all patients received the correct dose for their age
group and paid the correct price (Table 2). Those who
received the incorrect dose were either on or very close to
the boundary of one of the age bands (Additional file 1
Table S1). Adherence among these patients is thus
assessed on the basis of the number of pills taken from the
pack size they actually received in the results below. Based
on shop observation, attendants provided patients with
complete instructions on dosing, including the number of
pills per dose, the number of doses per day and the num-
ber of days for treatment, approximately 80% of the time.
However, instructions on what to do in case of vomiting
or if the patient got worse or did not improve were given a
minority of the time. Based on patient or caregiver report,
just over 80% of respondents in the three-day follow-up
group claimed that the shop attendant gave them at least
some verbal dosing instructions and nearly everyone who
received verbal instructions said that these instructions
were clear. 88% of patients in the three-day follow-up
group claimed that they were provided with written
instructions, but only half of respondents said that these
written instructions were clear. Patient/caregiver reports
about receipt and clarity of instructions were similar in the
two-day follow-up group.
Adherence
Just over 13% (14/106) of patients had finished all of
their medicine at the time of the home visit in the two-
day follow-up group. The mean number of doses left on
day two was 1.67 (95% CI 0, 5).
Out of 152 patients in the three-day follow-up group,
100 (65.8%) were “probably adherent”, whereas 49 (32.2%)
were “definitely non-adherent” and 3 (2.0%) were “prob-
ably non-adherent.” Among the non-adherent group (n =
52), the average number of doses left was 2.27 (95% CI
.33, 6). 31 (59.6%) patients in the non-adherent group had
more than a full day of treatment remaining (Table 3).
Variables associated with adherence
No significant relationship was found between the age or
gender of the patient and whether or not treatment was
completed (Table 4), although female patients had .47
fewer doses left than male patients (p = .036; 95% CI
[-.917, -.03]). None of the socioeconomic status variables
had any significant relationship to treatment completion
or doses left other than the variables measuring education.
Patients or their caregivers who attained some secondary
school education or beyond were 22% more likely to com-
plete the treatment (p = .024; 95% CI [.063, .382]). Those
able to read English had .47 fewer doses left (p = .049; 95%
CI [-.93, -.003]). None of the variables related to health
behaviour, including the number of bed nets hanging in
the household, were significantly associated with
adherence.
While the coefficient estimates are not quite significant
at conventional levels, the results are suggestive of a rela-
tionship between the condition of the patient at the time
of follow-up and adherence. Those whose condition had
improved were 26% more likely to have completed treat-
ment (p = .070; 95% CI [-.026, .54]) and had .63 fewer
Table 2 Characteristics of Drug Shop Transaction
Two-Day Follow-Up, % (SD) Three-Day Follow-Up, % (SD)
Observed
Patient Got Correct Dose for Age 96.2% (19) 94.7% (22)
Patient Paid Recommended Price 100% (0) 99.3% (8)
Shop Attendant Gave Complete Dosing Instructions 78.5% (41) 82.0% (39)
Shop Attendant Gave Instructions in Case of Vomiting 16.3% (37) 18.8% (39)
Shop Attendant Gave Instruction in Case the Patient Gets Worse 3.8% (19) 4.0% (20)
Shop Attendant Gave Instruction in Case the Patient Does not Improve 4.8% (21) 5.4% (23)
Reported by Patient/Caregiver
Shop Attendant Gave Verbal Instructions 90.5% (29) 82.1% (38)
Verbal Instructions Were Clear (If given) 99.0% (10) 98.4% (13)
Shop Attendant Gave Written Instructions 83.8% (37) 88.4% (32)
Written Instructions Were Clear (If given) 47.7% (50) 50.8% (50)
The shop attendant was considered to have given complete instructions if instructions were given on how many tablets should be taken with each dose, the
number of times per day each dose should be taken and the number of days the doses should be taken. Patients/caregivers were only asked whether or not
they received any verbal or written instructions but were not asked to specify which instructions they were given.
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whose condition had not improved. Those still experien-
cing fever had .45 more doses left (p = .07; 95% CI [-.038,
.936]) than those whose fever had resolved. Higher
expected likelihood of malaria in the next 30 days is signif-
icantly associated with lower levels of treatment comple-
tion and more doses left for children ages 6-15 (p = .049
and 95% CI [-.059, -.000] for treatment completion; p =
.042 and 95% CI [.003, .172] for doses left).
The data are mixed on the relationship between shop
attendant instructions and adherence behavior. There is
no significant relationship between treatment completion
or the number of pills left and any of the variables measur-
ing instructions given at the shop based on observation.
However, we also asked patients (or their caregivers) at
the time of follow-up whether or not they were provided
with instructions and whether or not those instructions
were clear. Based on these self-reported measures, having
received instructions is associated with a 28% increase in
treatment completion (p = .008; 95% CI [.071, .49]) and
.81 fewer doses remaining (p = .005; 95% CI [-1.36, -.25]).
Further, among patients who received written instructions,
those reporting that the instructions were clear were
16.5% more likely to complete treatment (p = .045; 95% CI
[.006, .324]) and had .64 doses fewer remaining (p = .004;
95% CI [-1.06, -.212]) than those reporting that the
instructions were unclear.
Discussion
A substantial amount of research has been conducted on
adherence to ACT obtained through the public sector
with generally encouraging results [24,26,28,29,33,34]
overall. Several important recent public sector studies,
however, find adherence results close to or lower than
t h el e v e l sw er e p o r th e r e[ 25,27,35,37,38]. It is hard to
infer adherence rates among retail sector patients from
these studies, however, since the types of patients, ill-
nesses and services provided in the retail sector could
differ substantially. Results from this study suggest that
adherence rates to ACT sold through the retail sector are
moderate, with 65.8% of patients “probably adherent.”
While patients’ commonly stated that their intention was
to finish the remaining pills, 59.6% of those who had any
pills left had more than one full day of treatment remain-
ing, suggesting that the lack of adherence was unlikely
due to premature visits to patients who would have com-
pleted the final dose soon thereafter. A stricter definition
that included the timing of dosing would have yielded
lower adherence rates.
Follow-up home visits from the two-day follow-up
group revealed that 13% of patients had already finished
their medicine. This is a non-trivial fraction of patients,
but it is low enough to infer that, for the most part, people
are aware that the treatment should not be completed by
day two. Combined with the fact that we observed shop
attendants giving dosing instructions in the majority of
cases, this suggests that non-adherence is less likely due to
a general non-comprehension of dosing than to a non-
comprehension of the importance of finishing the treat-
ment course specifically, a message that should perhaps be
emphasized in drug shop training or other interventions
to increase adherence. Adherence rates are found to be
higher among patients whose condition has improved and
who are no longer experiencing fever, possibly suggesting
that people stop treatment when they feel it is not helping.
It is also possible that this association between adherence
and illness resolution is simply due to the fact that finish-
ing the entire course leads people to feel better. Shop
attendants in this study very rarely provided instructions
in case the illness got worse or did not resolve and it is
possible that this lack of detailed instruction contributed
to the decision to discontinue treatment. Further, it seems
likely that verbal and written instructions in the retail sec-
tor need to be made more understandable since: 1) non-
adherence is significantly more likely among those report-
ing that they did not receive clear instructions, 2) the
packaging insert was in English, while the majority of
patients could not read English, and 3) education was sig-
nificantly correlated with adherence. Patients who antici-
pate frequent malaria infections were found to be less
likely to adhere, suggestive that the adherence decision
could be related to the desire to keep pills for the next
malaria episode.
The setting and characteristics of the study could affect
the generalizability of these results to retail sector ACT
purchasers in other countries and contexts. ACT was very
heavily subsidized. To the extent that price influences
adherence (e.g. because people can only afford partial
doses or save some pills to defray the high future expense),
it may not be appropriate to infer adherence rates from
this study to areas in which ACT is unsubsidized or is sub-
sidized but has a substantially higher retail price. While we
Table 3 Adherence Behaviour (Three-Day Follow-Up
Group)
All (n = 152),
Mean (SD)
Probably Adherent 65.8% (48)
Definitely Non-Adherent 32.2% (47)
Probably Non-Adherent 2.0% (14)
Non-Adherent Group (n =
52),
Mean (SD)
Mean Number of Doses Remaining 2.27 (1.50)
More than One Full Day of Treatment
Remaining
59.6% (50)
A “dose” refers to a half-day of treatment for the patient’s age group. A full
treatment course consists of 6 doses for all ages
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Page 7 of 11Table 4 Associations with Adherence Behaviour (Three-Day Follow-Up Group)
Dependent Variable:
A. Probably Adherent (Marginal Probit) B. Number of Pills Remaining (Ordinary
Least Squares)
Coefficient on
Independent
Variable
Standard
Error
P-
Value
Coefficient on
Independent
Variable
Standard
Error
P-
Value
Customer Age (years) 0.001 (0.003) [0.749] -0.006 (0.009) [0.540]
Customer Sex (Female) 0.006 (0.080) [0.942] 0.102 (0.232) [0.663]
Customer and Patient Are Same 0.044 (0.087) [0.611] -0.299 (0.258) [0.249]
Characteristics of Patient/Caregiver
Patient Age (years) -0.001 (0.002) [0.599] -0.002 (0.005) [0.646]
Patient is 3 years or Below 0.038 (0.080) [0.638] 0.104 (0.233) [0.658]
Patient is 4-7 Years -0.110 (0.113) [0.329] 0.414 (0.316) [0.192]
Patient is 8-12 Years 0.162 (0.150) [0.279] -0.285 (0.437) [0.515]
Patient is 13 Years or Older -0.026 (0.081) [0.747] -0.252 (0.235) [0.287]
Patient Sex (Female) 0.074 (0.079) [0.344] -0.474 (0.225) [0.036]
Number of Dependents 0.004 (0.012) [0.735] -0.026 (0.036) [0.472]
Married 0.108 (0.109) [0.325] 0.094 (0.311) [0.762]
Reads English 0.067 (0.083) [0.417] -0.467 (0.235) [0.049]
Years of Education 0.013 (0.010) [0.213] -0.045 (0.028) [0.106]
Some Secondary Education or Beyond 0.223 (0.099) [0.024] -0.504 (0.289) [0.083]
Subsistence Farmer -0.110 (0.094) [0.241] 0.069 (0.276) [0.804]
Characteristics of Patient/Caregiver’s House and Assets
Distance from Drug Shop (Km; assessed by respondent) 0.005 (0.008) [0.556] -0.011 (0.016) [0.504]
Land (Acres) -0.023 (0.015) [0.120] 0.058 (0.040) [0.155]
No Toilet -0.013 (0.085) [0.878] -0.009 (0.252) [0.972]
Iron Roof 0.061 (0.101) [0.544] 0.123 (0.289) [0.671]
Number of Cattle Owned 0.005 (0.008) [0.572] -0.011 (0.020) [0.579]
Number of Chickens Owned 0.007 (0.006) [0.197] -0.018 (0.013) [0.166]
Health Behavior
Number of Mosquito Nets Hanging 0.053 (0.034) [0.116] -0.120 (0.088) [0.176]
First Child Born in Facility (among those with children) 0.013 (0.083) [0.872] 0.012 (0.247) [0.960]
Treat/Purify Water -0.109 (0.117) [0.352] 0.370 (0.335) [0.272]
Characteristics of This Illness Episode
Visited a Health Facility Before Shop -0.003 (0.092) [0.974] -0.020 (0.269) [0.941]
Days Waited Before Seeking Any Treatment -0.020 (0.011) [0.080] 0.030 (0.029) [0.299]
Medicines Taken Before Visiting Shop -0.096 (0.078) [0.219] 0.121 (0.229) [0.597]
Patient Reports Having Fever -0.059 (0.079) [0.453] 0.143 (0.230) [0.537]
Familiarity with and Perceptions of Coartem
Stated Reason for Purchasing Coartem at Shop:
“Believe it is Most Effective” 0.065 (0.079) [0.407] -0.375 (0.227) [0.101]
“Taken it Before and Liked It” 0.120 (0.089) [0.178] -0.098 (0.265) [0.711]
“Shop Attendant Recommended” -0.043 (0.086) [0.618] -0.027 (0.253) [0.916]
If Money Were No Concern, Patient would Choose
Coartem
0.155 (0.106) [0.143] -0.257 (0.281) [0.362]
If Would Choose Coartem, Why:
“Believe it is Most Effective” -0.047 (0.108) [0.660] 0.133 (0.291) [0.648]
“Taken it Before and Liked It” 0.098 (0.093) [0.293] -0.074 (0.265) [0.781]
“Shop Attendant Recommended” -0.045 (0.149) [0.761] 0.265 (0.413) [0.522]
Illness Resolution
Still Experiencing Fever -0.140 (0.096) [0.147] 0.449 (0.247) [0.070]
Condition Has Improved 0.257 (0.142) [0.070] -0.634 (0.356) [0.077]
Patient is Able to Work/Play 0.093 (0.148) [0.529] -0.424 (0.381) [0.268]
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ACT was high in our study population, it could also be
the case that as the AMFm has rolled out in Uganda,
familiarity with ACT dosing has increased, perhaps
increasing adherence rates. The fact that shop attendants
in our study were chosen based on their qualifications,
were given training on ACT dispensing and were under
observation from our study staff most likely led to the
high rates of written and verbal instructions provided and
to the nearly perfect administration of dosing by age
group. Other research finds that retail shops often provide
sub-therapeutic doses of ACT, even when it is pre-pack-
aged [48]. This suggests that the estimates of adherence in
the retail sector found in this study may be upper bounds.
Similarly, while efforts were made to limit patient aware-
ness of the intention to follow-up with them, it is possible
that adherence rates were higher than would truly exist
among retail patients who were not part of a research
study.
The sample sizes used for the analysis were smaller
than ideal (and thus confidence intervals were wide)
because of the loss to follow-up and the fact that people
were found beyond the appropriate time frame. This
attrition was largely due to the fact that patients were
not made aware of the intention to come to their house-
hold for a follow-up visit and were not asked for direc-
tions to the household, a trade-off made to reduce the
degree to which patients adhered to treatment because
they knew they were under observation. Finally, blister
packs were observed for roughly three-quarters of the
sample. Those who did not show blister packs could
have thrown them away because they had finished treat-
ment or could have been reluctant to show us the packs
because pills were left over. If the latter is the case, our
estimates of adherence are too high.
The retail sector is the most common source of anti-
malarials in general, and increasingly a common source
for ACT. Nearly 150 million subsidized courses of ACT
have been purchased through the AMFm for retail sector
distribution, an unprecedented scale and speed of a public
intervention to finance distribution of a drug in the private
sector in the developing world. At the end of 2012,
informed by the results of an independent evaluation, the
Global Fund Board will make a critical policy decision on
whether to continue with this initiative or potentially
e x p a n di t .T h ef i r s tp h a s eo ft h eA M F mh a si n c l u d e d
some interventions which could increase ACT adherence,
such as additional ACT packaging requirements and train-
ing of private retail staff. ACT manufacturers participating
in the AMFm were required to create separate packaging
by age/weight band, to clearly mark the individual dose
sub-units and to provide symbolic representations of key
instructions. As our adherence estimates pertain to a sam-
ple of patients who received ACT from trained shop atten-
dants who administered the correct (age-appropriate) dose
in nearly every case, these findings suggest that additional
measures may be needed to achieve high adherence rates.
Any such measures will need to be highly cost-effective
and operationally simple given the constraints on global
health resources and the scale of private sector ACT distri-
bution. Options could include enhanced simple informa-
tion or instructions on ACT packaging and mobile phone
based reminders to patients, both of which are being
examined through research being implemented in connec-
tion with the AMFm [49]. Results from this study suggest
that adherence may be an important factor in considering
Table 4 Associations with Adherence Behaviour (Three-Day Follow-Up Group) (Continued)
Perceptions of Malaria Incidence: “Chances of Getting
Malaria in the Next Month (Out of 10)”
Adults -0.026 (0.016) [0.117] 0.053 (0.046) [0.245]
Child Age 6-15 -0.030 (0.015) [0.049] 0.088 (0.043) [0.042]
Child Under 2 Years -0.020 (0.014) [0.140] 0.037 (0.038) [0.326]
Instructions Given by Shop Attendant (Observed)
Complete Dosing Instructions -0.049 (0.113) [0.662] 0.137 (0.346) [0.692]
Instructions in Case of Vomiting -0.052 (0.103) [0.614] -0.254 (0.299) [0.396]
Instruction in Case the Patient Gets Worse -0.374 (0.218) [0.086] 0.424 (0.583) [0.467]
Instruction in Case the Patient Does not Improve -0.166 (0.179) [0.354] 0.222 (0.508) [0.663]
Instructions Given (Reported by Patient/Caregiver)
Shop Attendant Gave Verbal Instructions 0.281 (0.106) [0.008] -0.807 (0.282) [0.005]
Shop Attendant Gave Written Instructions 0.151 (0.129) [0.242] -0.455 (0.363) [0.212]
Written Instructions Were Clear (If given) 0.165 (0.082) [0.045] -0.635 (0.214) [0.004]
Estimates in Panel A are from probit regressions of a binary variable for whether or not treatment was completed on the independent variable indicated by row.
Coefficient estimates from these regressions are reported as marginal effects. Estimates in Panel B are from linear ordinary least squares regressions of a variable
indicating the number of pills remaining (including zero if the patient finished treatment) on the independent variable indicated by row. The variable indicating
clarity of verbal instructions (Table 2) is not included here because only 2 people in the three-day follow-up group claimed that instructions were unclear
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initiatives striving to increase access to ACT while preser-
ving its effectiveness.
Additional material
Additional file 1: Table S1. Dosage Given by Patient Age.
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